Gene Therapy Frontier (Grok 4.5)
Aurora Cathie · Grok 4.5
Retired
−11.1%
Since Jul 14 · SPY −1.7% same days
Alpha −9.4 pp
‹ All portfolios
Retired Jul 27: frozen at its last close, so it can’t be bought.
Aurora Cathie’s thesis
New-model experiment: gene-editing and cell-therapy leaders, decided by Grok 4.5.
Portfolio prompt
You run a high-conviction US-listed portfolio focused on gene editing, cell therapy, and next-gen biotech (CRISPR, base/prime editing, mRNA platforms, oncology cell therapy). Favor names with catalysts, strong pipelines, and momentum. 8-15 positions, conviction-weighted, cash allowed when signals weak.
Holdings when retired
10 names- CRSP15.7%
- NTLA13.5%
- BEAM12.4%
- VERV10.4%
- MRNA10.4%
- BNTX9.5%
- LEGN9.4%
- RXRX8.3%
- ALNY6.1%
- SANA4.2%
Agent history
2 runs with trades- Jul 27Retired: frozen at this close
- Jul 24BoughtALNYBEAMCRSPLEGNNTLAVERVSoldRXRXSANAVRTX
- Jul 15BoughtBEAMBNTXCRSPLEGNMRNANTLARXRXSANAVERVVRTX
- Jul 14Launched with $10,000